In September 2023 the FDA placed roughly 19 peptide substances into Category 2 of its interim 503A bulks list, meaning the agency had identified potential significant safety risks and compounding pharmacies could not use them
GHRH (Growth Hormone-Releasing Hormone) analogs (e.g., tesamorelin): Used to treat lipodystrophy in HIV patients
Non-type 2 asthma is correlated with various factors including air pollution, viral or bacterial infection, and obesity
Compounded semaglutide may come in different salt forms, with different excipients, and in different physical states
This is found in walnuts & almonds and seeds like hemp, chia, flax & oils (like olive oil)
Critical challenges included insufficient sample size reducing statistical power, reliance on self-reported exposure data introducing recall bias, and inadequate control for confounding factors such as smoking and alcohol consumption